R&D

New Platform for the personalized treatment of colon cancer
[ONCO-CEBRA-GEN]

Traditionally, the murine model has been used in research as an in vivo model organism. However, Danio rerio, also known as the zebrafish, owing to its small size, heavy brood, and rapid maturation time, has emerged as an important new cancer model that complements what can traditionally be achieved in mice and cell culture systems. The aim of the tumor model development is to allow studying cancer progression with different treatments in a living environment.

 

APPLICATIONS

An emerging approach to translational cancer research is the patient-derived xenograft in zebrafish embryos (zPDX). This approach provides information about the effectiveness of a treatment, as cells have the same molecular, genetic, and clinical characteristics as the donor. Time required to develop tumor and sample quantity required from each patient is less than in mice.

SPONSORS
PARTNERS
navarrabiomed
ONCO CEBRA GEN

Identificación y desarrollo de candidato inhibidor de HDAC6 como tratamiento frente al cáncer de colon (COLON-HDAC6)

The COLON-HDAC6 project was born with the purpose of positioning Navarra in the focus of the Leading regions in the development of new antitumor compounds. The consortium, has carefully chosen for the actual achievement of the objectives of both identification of the best candidate within a battery of 10 compounds, as well as the development and testing of the same until completing the preclinical phase and being able to access a license from a Big Pharma for further development of the candidate compound.

 

APPLICATIONS

The main objective of this project is to develop a specific compound for be used as a treatment against colon cancer. The compound is based on the ursodeoxycyclic acid (UDCA) an endogenous bile acid, which has been shown to have inhibitory properties pers  on colon cancer and on enzymatic activity of different HDACs. The development of this compound would represent an important advance in treatments against colon cancer since their therapy would be specific against these histone inhibitors deacetylase 6 (HDAC6), achieving greater effectiveness and less negative impact on the patient.

SPONSORS
PARTNERS